Roberts Eiry's Form 4 filing
Neurocrine Biosciences IncNBIX · filed Feb 14, 2025
- Accession no.
- 0000914475-25-000069
- Filed
- Feb 14, 2025
- Trade date
- Feb 12-14, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 5 derivative transactions. Open-market sales total $258.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Roberts EiryCIK 0001727606 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | Common Stock | MOption exerciseAcquired | +2,113 | $0.00 | $0 | 35,366 | Direct | |
| Feb 13, 2025 | Common Stock | SSaleDisposed | −1,114 | $116.90F2 | −$130,226.6 | 34,252 | Direct | |
| Feb 13, 2025 | Common Stock | MOption exerciseAcquired | +1,120 | $0.00 | $0 | 35,372 | Direct | |
| Feb 13, 2025 | Common Stock | SSaleDisposed | −604 | $116.74F4 | −$70,510.96 | 34,768 | Direct | |
| Feb 13, 2025 | Common Stock | MOption exerciseAcquired | +1,372 | $0.00 | $0 | 36,140 | Direct | |
| Feb 14, 2025 | Common Stock | SSaleDisposed | −500 | $115.04F5 | −$57,520 | 35,640 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | Common Stock | AGrant or awardAcquired | +43,261 | $0.00 | $0 | 43,261 | Direct | |
| Feb 12, 2025 | Common Stock | AGrant or awardAcquired | +8,108 | $0.00 | $0 | 8,108 | Direct | |
| Feb 13, 2025 | Common Stock | MOption exerciseDisposed | −2,113 | $0.00 | $0 | 4,227 | Direct | |
| Feb 13, 2025 | Common Stock | MOption exerciseDisposed | −1,120 | $0.00 | $0 | 3,363 | Direct | |
| Feb 13, 2025 | Common Stock | MOption exerciseDisposed | −1,372 | $0.00 | $0 | 4,115 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F5
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.